Varda Space Industries has signed its first major pharmaceutical partnership, agreeing with United Therapeutics to develop drug formulations in microgravity that cannot be produced on Earth. The deal, announced May 13, marks a turning point for the El Segundo company’s effort to convert orbital manufacturing from a research curiosity into a commercial supply chain.
The collaboration will start with treatments for rare pulmonary diseases, an area where United Therapeutics already commands a substantial commercial footprint. Varda’s W-series reentry spacecraft will carry the formulation experiments to low Earth orbit and return them to a desert landing site within weeks.
A bet on crystals you cannot grow on Earth
The scientific premise behind the partnership is straightforward. On Earth, gravity drives sedimentation and convection currents that distort how protein and small-molecule crystals form. In free fall, those forces vanish, and crystals can assemble into geometries that are either purer, more uniform, or simply unavailable in a terrestrial lab. Different crystal structures of the same drug can dissolve differently, last longer in storage, or bind differently to their biological targets.
In the joint announcement of the agreement, Varda CEO Will Bruey said microgravity gives the partners a fundamentally different environment to manufacture pharmaceuticals that are otherwise impossible on Earth, and Martine Rothblatt, chair and CEO of United Therapeutics, framed the collaboration as a way to explore how space-based manufacturing could contribute to significant improvements for rare pulmonary disease treatments.
Speaking to MIT Technology Review, Rothblatt confirmed that United Therapeutics is paying Varda to help identify new crystal forms, known as polymorphs, of its drugs, with the hope that some may have improved properties.
Why a capsule beats a space station
For two decades, microgravity pharmaceutical research has been bottlenecked by the International Space Station. Experiments competed for crew time, fit around station schedules, waited months for return flights, and were subject to whatever vibration and contamination the orbital lab happened to produce. The result was a body of promising results that rarely scaled into manufacturing pipelines.
Varda’s pitch is that an automated, free-flying capsule changes the economics. Each W-series mission is dedicated to its customer’s payload. There is no astronaut overhead, no shared schedule, and the spacecraft can be designed around the chemistry rather than the other way around. The company has stated a goal of monthly flight cadence.
That cadence is now backed by infrastructure. Varda has flown multiple reentry missions to date, with W-6 launched in March 2026, and additional missions in development.
The capital base behind the move
The United Therapeutics deal lands roughly ten months after Varda closed a Series C round of $187 million in July 2025, led by Natural Capital and Shrug Capital with participation from Founders Fund, Khosla Ventures, Lux Capital and others. That financing brought total capital raised to $329 million.
Varda explicitly earmarked the Series C proceeds for two things: flight cadence and a dedicated pharmaceutical lab. The company opened a 10,000-square-foot facility in El Segundo to support drug formulation work, reflecting an investment in the belief that in-space pharmaceutical manufacturing will drive the foundation of the orbital economy.
Independent industry coverage has echoed that framing. BioProcess International reported on the funding round in the context of a broader push to build orbital pharmaceutical production lines rather than one-off science demonstrations, noting that Varda’s stated focus extends across small molecules and monoclonal antibodies.
Why rare pulmonary disease, and why United Therapeutics
The choice of disease target is not incidental. United Therapeutics built its business on treatments for pulmonary arterial hypertension, a rare and lethal condition where patients tolerate complex therapies and payers tolerate high prices because alternatives are scarce. Rare diseases are exactly the category where a microgravity-enabled drug improvement can pay for the cost of orbital manufacturing.
A common monoclonal antibody, by contrast, would have to compete on cost with terrestrial fermentation at scale. The United Therapeutics deal points at a more immediate path: low-volume, high-value molecules where each gram is worth flying.
The wider commercial logic is one pharma is familiar with. Companies routinely try to keep blockbuster franchises alive by reformulating drugs, switching delivery mechanisms, or finding new crystal forms that extend patent protection. Varda is offering microgravity as another tool in that same kit, one that happens to require a rocket.
The biological case for microgravity
The deeper scientific argument for orbital biology is still being assembled. Recent work has documented how microgravity reshapes biological systems in ways that ground research cannot replicate. Space Daily has covered findings on unusual virus-bacteria dynamics aboard the ISS and on reversible shifts in astronaut epigenetic age, both of which point at a recurring pattern: living and crystalline systems behave differently in orbit, and those differences are sometimes useful.
Translating that scientific signal into a manufacturing business has been the missing piece. Varda is now testing whether a pharma partner with a clear commercial target will pay for orbital chemistry the way the Defense Department pays for hypersonic reentry data.
The hypersonics hedge
That second revenue line matters. Each Varda capsule that returns from orbit collects data on the hypersonic flight regime as it falls through the atmosphere, and the Air Force Research Laboratory awarded Varda a four-year, $48 million contract in late 2024 to fly military payloads on those reentries under a program called Prometheus. The hypersonics business gives Varda a paying customer regardless of how quickly the pharmaceutical pipeline matures.
It also matters for a company that is asking pharma partners to bet on a delivery system. United Therapeutics is not just buying microgravity time. It is buying confidence that Varda can fly, return, and repeat. Successful missions, an in-house satellite bus, and established landing infrastructure all serve that argument.
What the deal actually proves
A first-of-its-kind agreement between a five-year-old space startup and a publicly traded biotech does not, on its own, establish that orbital drug manufacturing is a real industry. Crystals grown on W-series missions still have to clear the same regulatory bar as anything else United Therapeutics develops, and the economics of returning grams of active pharmaceutical ingredient from orbit remain unproven at commercial volumes.
What the deal does prove is that a pharmaceutical executive with a profitable franchise is willing to spend real money testing the proposition. For Varda, that validation is the asset. For the wider space economy, it is one of the cleaner data points yet that demand for orbital infrastructure can come from somewhere other than government contracts and satellite communications.
The first formulations from the partnership will fly on upcoming W-series missions. Whether they yield a marketable drug is a question for the labs and the regulators. Whether they yield a viable business model is a question Varda has now begun to answer.
Articles cover space industry news and the Mind & Meaning pillar (human psychology, ambition, isolation, meaning under extremes). The Space Daily Editorial Team produces content through a collective process: research, source verification, drafting, technical review, and editing. Articles under this byline reflect the team’s editorial judgment rather than a single writer’s. Space Daily takes editorial responsibility for content published under this byline. See our editorial policy for more on how we work.
Photo by Pavel Danilyuk on Pexels
